Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Remeglurant (INNTooltip International Nonproprietary Name; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.
See also
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). World Health Organization.
- US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolopyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
- ^ "Remeglurant". Adis Insight. Springer Nature Switzerland AG.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |